Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
about
Neuroendocrine hormone amylin in diabetesIn silico design of optimal ratio for co-administration of pramlintide and insulin in type 1 diabetes.Pramlintide and the treatment of diabetes: a review of the data since its introduction.Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.Optimal control of blood glucose: the diabetic patient or the machine?Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetesPramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk.Role of postprandial hyperglycemia in cardiovascular disease.Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemiaReview of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes.Closed-loop insulin delivery: from bench to clinical practice.Role of Amylin in Type 1 and Type 2 Diabetes.Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.Through the looking glass: current and future perspectives on the role of hormonal interplay in glucose homeostasis.Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis.Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetesA model of glucose-insulin-pramlintide pharmacokinetics and pharmacodynamics in type I diabetes.Amylin replacement therapy in patients with type 1 diabetes.Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use.The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.Adolescents with type 1 diabetes: family functioning and metabolic control.Therapy of Type 1 Diabetes Mellitus
P2860
Q26751000-1EEB26E4-6E2F-42BE-98B6-1F37DE5BFC51Q30410405-FF7C31E0-F97E-452D-8B87-CE49275D61FAQ33896433-6835D452-619D-4E27-BDA6-4CF4C5D8137AQ36012965-54DA510C-6CDC-4B4F-94CC-D52A30301F87Q36206226-29AAA9F9-F4A4-40FC-AB32-7823990D10A7Q36249631-38128329-7FEA-4017-802C-DDD037470505Q37193917-343E4137-0AA4-49E4-9F18-2A5B20F78258Q37197094-F0A550B6-FCF5-4461-9F67-52FB4FFAA174Q37198017-668A021B-CA30-42CD-8983-D584BD971AE9Q37385620-5F35934E-D8FF-4191-8544-2CDE75A643CFQ37846089-1120B10E-E570-4EEA-AE77-5C770CB757AEQ38596374-8936656F-F167-4913-A1AD-13F8EC5B6D26Q39040207-B1D63D28-0757-446E-9DF6-C63D29B5A7CBQ39101008-45E30B61-2932-429C-8D97-5DF29E1AD7DDQ40215795-268EFCF7-C363-4FCD-8291-800BD36C26F3Q42371659-31E3EA0E-30CC-47A4-9CDF-19B752813DAAQ42578315-FC326156-C316-4FF7-A633-F379284B0E39Q42723586-47AD5DE0-96DA-4D97-87B6-B0D5C79470CDQ46047804-0441DC16-DECF-49DA-AFF1-91808F117DF9Q46108345-06B20B4F-2823-47DD-BEE3-479587AAE886Q46934886-1765BDCF-DE6E-4BAD-9A35-DFDE53741A67Q51321231-972CA2BD-71E6-4EC9-B8D6-3DFAE978EC63Q57412611-BB54F06A-515E-4F80-BC55-73B208044095
P2860
Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Pramlintide reduces postprandi ...... diabetes: a dose-timing study.
@en
Pramlintide reduces postprandi ...... diabetes: a dose-timing study.
@nl
type
label
Pramlintide reduces postprandi ...... diabetes: a dose-timing study.
@en
Pramlintide reduces postprandi ...... diabetes: a dose-timing study.
@nl
prefLabel
Pramlintide reduces postprandi ...... diabetes: a dose-timing study.
@en
Pramlintide reduces postprandi ...... diabetes: a dose-timing study.
@nl
P2093
P1433
P1476
Pramlintide reduces postprandi ...... diabetes: a dose-timing study.
@en
P2093
Alan Gottlieb
Christian Weyer
David G Maggs
Dennis D Kim
James A Ruggles
Karen Lutz
Maria Gutierrez
Orville G Kolterman
Sherwyn Schwartz
P304
P356
10.2337/DIACARE.26.11.3074
P407
P577
2003-11-01T00:00:00Z